Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 15/20 | 0.51 |
| ▸ | CCNA2 | P20248 | 8/20 | 0.51 |
| ▸ | CDK4 | P11802 | 8/20 | 0.51 |
| ▸ | PLK1 | P53350 | 1/20 | 0.51 |
| ▸ | CDK8 | P49336 | 2/20 | 0.50 |
| ▸ | CCNC | P24863 | 1/20 | 0.50 |
| ▸ | CDK9 | P50750 | 12/20 | 0.49 |
| ▸ | CCNT1 | O60563 | 7/20 | 0.49 |
| ▸ | CDK1 | P06493 | 8/20 | 0.49 |
| ▸ | CDK7 | P50613 | 8/20 | 0.49 |
| ▸ | CCNB1 | P14635 | 4/20 | 0.49 |
| ▸ | CCNH | P51946 | 4/20 | 0.49 |
| ▸ | AURKA | O14965 | 5/20 | 0.48 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.48 |
| ▸ | WEE1 | P30291 | 2/20 | 0.48 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29629247 | 0.92 | CDK2 (0.51) | CDK2CCNA2CDK4PLK1CDK9 | |
| SCHEMBL22684844 | 0.92 | CDK2 (0.51) | CDK2CCNA2CDK4PLK1CDK9 | |
| SCHEMBL22684884 | 0.88 | CDK2 (0.47) | CDK2CCNA2CDK4PLK1CDK8 | |
| SCHEMBL23068687 | 0.88 | SMN1; SMN2 (0.59) | CDK2CCNA2CDK4PLK1CDK9 | |
| SCHEMBL23068630 | 0.86 | CDK2 (0.58) | CDK2CCNA2CDK4PLK1CDK9 | |
| SCHEMBL23068629 | 0.86 | RAB9A (0.46) | CDK2CDK4MEN1KMT2AKDM4E | |
| SCHEMBL23068665 | 0.86 | BRAF (0.54) | CDK2CCNA2CDK4PLK1CDK8 | |
| SCHEMBL29629210 | 0.86 | BRAF (0.54) | CDK2CCNA2CDK4PLK1CDK8 | |
| SCHEMBL23068631 | 0.86 | CDK2 (0.48) | CDK2CCNA2CDK4PLK1CDK8 | |
| SCHEMBL29629220 | 0.86 | CDK2 (0.48) | CDK2CCNA2CDK4PLK1CDK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3740484-B1 | 5-(PYRIMIDIN-4-YL)THIAZOL-2-YL UREA DERIVATIVES AS THERAPEUTIC AGENTS | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2024-09-11 | — | — | EP | disclosed |
| CN-111757881-B | 5- (Pyrimidin-4-yl) thiazol-2-yl urea derivatives as therapeutic agents | 澳升医药公司 | 2024-05-07 | — | — | CN | disclosed |
| US-20230092876-A1 | 5-(PYRIMIDIN-4-YL)THIAZOL-2-YL UREA DERIVATIVES AS THERAPEUTIC AGENTS | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2023-03-23 | — | — | US | disclosed |
| US-11325900-B2 | 5-(pyrimidin-4-yl)thiazol-2-yl urea derivatives as therapeutic agents | AUCENTRA HOLDINGS PTY LTD (AU) | 2022-05-10 | — | — | US | disclosed |
| US-11325900-B2 | 5-(pyrimidin-4-yl)thiazol-2-yl urea derivatives as therapeutic agents | AUCENTRA HOLDINGS PTY LTD (AU) | 2022-05-10 | — | — | US | disclosed |
| US-20210070746-A1 | 5-(PYRIMIDIN-4-YL)THIAZOL-2-YL UREA DERIVATIVES AS THERAPEUTIC AGENTS | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2021-03-11 | — | — | US | disclosed |
| US-20210070746-A1 | 5-(PYRIMIDIN-4-YL)THIAZOL-2-YL UREA DERIVATIVES AS THERAPEUTIC AGENTS | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2021-03-11 | — | — | US | disclosed |
| EP-3740484-A1 | 5-(PYRIMIDIN-4-YL)THIAZOL-2-YL UREA DERIVATIVES AS THERAPEUTIC AGENTS | AUCENTRA HOLDINGS PTY LTD (AU) | 2020-11-25 | — | — | EP | disclosed |
| CN-111757881-A | 5- (pyrimidin-4-yl) thiazol-2-ylurea derivatives as therapeutic agents | 澳升控股有限公司 | 2020-10-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230092876-A1 | 5-(PYRIMIDIN-4-YL)THIAZOL-2-YL UREA DERIVATIVES AS THERAPEUTIC AGENTS | CDK8, CDK18, CDK9 | CDK2 8/4885CCNA2 34/4885CDK4 13/4885 |
| US-11325900-B2 | 5-(pyrimidin-4-yl)thiazol-2-yl urea derivatives as therapeutic agents | CDK8, CDK18, CDK9 | CDK2 8/4885CCNA2 34/4885CDK4 13/4885 |
| US-20210070746-A1 | 5-(PYRIMIDIN-4-YL)THIAZOL-2-YL UREA DERIVATIVES AS THERAPEUTIC AGENTS | CDK8, CDK18, CDK9 | CDK2 8/4885CCNA2 34/4885CDK4 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.